These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 16669517)

  • 1. Drug lawsuits building. Merck, Pfizer facing charges of misrepresentation.
    Benko LB
    Mod Healthc; 2006 Apr; 36(15):16. PubMed ID: 16669517
    [No Abstract]   [Full Text] [Related]  

  • 2. Vioxx doctors wooed by Merck are now its foes.
    Tesoriero HW
    Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911
    [No Abstract]   [Full Text] [Related]  

  • 3. Disease management and antikickback regulations.
    Kozma CM
    Manag Care Interface; 2003 Dec; 16(12):34-5. PubMed ID: 14750462
    [No Abstract]   [Full Text] [Related]  

  • 4. Merck cleared in personal injury case against Vioxx.
    Mayor S
    BMJ; 2005 Nov; 331(7525):1101. PubMed ID: 16282390
    [No Abstract]   [Full Text] [Related]  

  • 5. Vioxx may go back on sale after scraping past FDA panel.
    Wadman M
    Nature; 2005 Feb; 433(7028):790. PubMed ID: 15729304
    [No Abstract]   [Full Text] [Related]  

  • 6. Merck pays $1bn penalty in relation to promotion of rofecoxib.
    Tanne JH
    BMJ; 2011 Nov; 343():d7702. PubMed ID: 22123916
    [No Abstract]   [Full Text] [Related]  

  • 7. Vioxx award good news for Canadian lawsuits.
    Eggertson L
    CMAJ; 2005 Sep; 173(7):744. PubMed ID: 16186576
    [No Abstract]   [Full Text] [Related]  

  • 8. US drug companies paid $15bn in fines for fraudulent marketing in past five years.
    Tanne JH
    BMJ; 2010 Dec; 341():c7360. PubMed ID: 21177361
    [No Abstract]   [Full Text] [Related]  

  • 9. Merck to pay $5bn in rofecoxib claims.
    Charatan F
    BMJ; 2007 Nov; 335(7628):1011. PubMed ID: 18006982
    [No Abstract]   [Full Text] [Related]  

  • 10. Make or break time in Vioxx drama.
    Nature; 2006 Mar; 440(7082):277. PubMed ID: 16541045
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmaceutical industry and payer partnerships: legal update.
    Goldstein WC
    Manag Care; 2001 Sep; 10(9 Suppl):5-6; discussion 9-12. PubMed ID: 11729439
    [No Abstract]   [Full Text] [Related]  

  • 12. The preacher who's raising hell with Merck.
    Parloff R
    Fortune; 2005 Aug; 152(3):20. PubMed ID: 16097189
    [No Abstract]   [Full Text] [Related]  

  • 13. Johnson & Johnson to pay $2.2bn to settle charges of false marketing on three drugs.
    Kmietowicz Z
    BMJ; 2013 Nov; 347():f6696. PubMed ID: 24196512
    [No Abstract]   [Full Text] [Related]  

  • 14. Merck appeals rofecoxib verdict.
    Tanne JH
    BMJ; 2007 Mar; 334(7594):607. PubMed ID: 17379897
    [No Abstract]   [Full Text] [Related]  

  • 15. "Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions.
    Chodock R; Yolkut D; Connolly DR
    Tort Trial Insur Pract Law J; 2005; 40(3):997-1017. PubMed ID: 16100814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cyclooxygenase inhibitors: a never ending story?].
    Macrì R; Manfredi C
    G Ital Cardiol (Rome); 2006 Jul; 7(7):505-7. PubMed ID: 16977790
    [No Abstract]   [Full Text] [Related]  

  • 17. Despite warnings, drug giant took long path to Vioxx recall.
    Berenson A; Harris G; Meier B; Pollack A
    N Y Times Web; 2004 Nov; ():A1, A32. PubMed ID: 15599982
    [No Abstract]   [Full Text] [Related]  

  • 18. US judge dismisses 50m dollars damages in Vioxx lawsuit.
    Charatan F
    BMJ; 2006 Sep; 333(7567):516. PubMed ID: 16960199
    [No Abstract]   [Full Text] [Related]  

  • 19. Former drug execs lose appeal. Bid for re-entry to Medicare is denied.
    Rhea S
    Mod Healthc; 2010 Dec 20-27; 40(51):14. PubMed ID: 21344720
    [No Abstract]   [Full Text] [Related]  

  • 20. Professional pill pusher.
    Meyer CR
    Minn Med; 2005 Mar; 88(3):4. PubMed ID: 15852581
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.